Drug induced toxic epidermal necrolysis: Two case reports

Cases Journal

Volumn 2, Issue 9, 2009, Pages

  Qadir, Syed Nurul Rasool ^a   Raza, Naeem ^b   Qadir, Fozi ^c  

^a Peshawar Cantonment   (Pakistan)

^b PAF Hospital Faisal   (Pakistan)

^c Military Hospital   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFTRIAXONE; COTRIMOXAZOLE; DEXAMETHASONE; INSULIN; MOXIFLOXACIN; TETRACYCLINE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CAUCASIAN; CORTICOSTEROID THERAPY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REDUCTION; FEMALE; HUMAN; MALE; PAKISTAN; PLASMA TRANSFUSION; TOXIC EPIDERMAL NECROLYSIS; WOUND DRESSING;

EID: 77953409538     PISSN: 17571626     EISSN: None     Source Type: Journal    
DOI: 10.4076/1757-1626-2-7765     Document Type: Article

References (15)

1. Hurwitz RM, Rivera HP, Gooch MH, Slama TG, Handt A, Weiss J: Toxic shock syndrome or Toxic epidermal necrolysis? Case reports showing clinical similarity and histological seperation. J Am Acad Dermatol 1982, 7:246-254.
2. Guillaume JC, Roujeau JC, Revuz J, Penso D, Touraine R: The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol 1987, 123:1166-1170.
3. Stern RS, Chan HL: Usefullness of case report literature in determining drugs responsible for toxic epidermal necrolysis. J Am Acad Dermatol 1989, 21:317-322.
4. Garcia-Doval I, Le Cleach L, Bocquet H, Otero XL, Roujeau JC: Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death. Arch Dermatol 2000, 136:323-327.
5. Roujeau JC, Chosidow O, Saiag P, Guillaume JC: Toxic epidermal necrolysis (Lyell's syndrome). J Am Acad Dermatol 1990, 23: 1039-1058.
6. Correia O, Delgado L, Roujeau JC, LeCleach L, Flemming-Torrinha JA: Soluble interleukin 2 receptor and interleukin 1-alpha in Toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. Arch Dermatol 2002, 138:29-32.
7. Revuz J, Penso D, Roujeau JC: Toxic epidermal necrolysis: clinical findings and prognostic factors in 87 patients. Arch Dermatol 1987, 123:1160-1165.
8. st edition. Edited by Chapman LE. Philadelphia: WB Saunders & Co; 1988:122-132.
9. th edition. Edited by Champion RH, Pye RJ. Edinburgh: Churchill-Livingstone; 1990:85-99.
10. Revuz J, Roujeau JC, Guillaume JC, Penso D, Touraine R: Treatment of toxic epidermal necrolysis: Creteil's experience. Arch Dermatol 1987, 123:1156-1158.
11. Guibal F, Bastuji-Garin D, Chosidow O, Saiag P, Revuz J, Roujeau JC: Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 1995, 131:669-672.
12. Heimbach DM, Engrav LH, Marvin JA, Harnar TJ, Grube BJ: Toxic epidermal necrolysis: a step forward in treatment. JAMA 1987, 257:2171-2175.
13. Halebian PH, Carder VJ, Madden MR, Finklestein JL, Shires GT: Improved burn center survival in patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986, 204:503-512.
14. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE: Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: Multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003, 139:26-32.
15. Trent JT, Kisner RS, Romanelli P, Kerdel FA: Analysis of intravenous immunoglobulins for treatment of toxic epidermal necrolysis using SCORTEN. Arch Dermatol 2003, 139:39-43.